This site is intended for Healthcare Professionals only

Tremfya launched for psoriasis

Clinical

Tremfya launched for psoriasis

Janssen has launched guselkumab (Tremfya) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Janssen says that guselkumab is the first biologic to “selectively target interleukin-23, a key protein that initiates a specific immune inflammatory response”.

Copy Link copy link button

Clinical

Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.

Share: